← Back to patent-cliff list
索磷布韦/维帕他韦
Tier B — Position earlySofosbuvir/Velpatasvir
Gilead Inc
Originator
2016
First approval
-
Expiry (public)
$3.51B ▲
Peak sales
化学药
Type
Targets：NS5B、NS5A
Brand：Epclusa、丙通沙
Indications (approved)：丙型肝炎、慢性丙型肝炎
Regional status
US
批准上市
2016-06-28
EU
批准上市
2016-07-06
China
批准上市
2018-05-23
Japan
批准上市
2019-01-08
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sofosbuvir/Velpatasvir?
Approved indications include: 丙型肝炎, 慢性丙型肝炎.
When does the Sofosbuvir/Velpatasvir patent expire?
No public expiry year is available for Sofosbuvir/Velpatasvir yet; this page updates once verified.
How do I get a quote for Sofosbuvir/Velpatasvir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24